Patients must perform a pregnancy test monthly during therapy and for 6 months post therapy.Female patients of childbearing potential and male patients with female partners of childbearing potential must be advised of the teratogenic/embryocidal risks and must be instructed to practice effective contraception during Ribavirin therapy and for 6 months post therapy. Ribavirin is sometimes given to people taking other antiviral medications to treat hepatitis C. Reports of fatal hepatic failure as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in clinical trials [see In Study NR15961, patients who were administered zidovudine in combination with peginterferon alfa-2a/Ribavirin developed severe neutropenia (ANC less than 500) and severe anemia (hemoglobin less than 8 g/dL) more frequently than similar patients not receiving zidovudine (neutropenia 15% vs. 9%) (anemia 5% vs. 1%). Ribavirin tablets in combination with peginterferon alfa-2a are indicated for the treatment of patients 5 years of age and older with chronic hepatitis C (CHC) virus infection who have compensated liver disease and have not been previously treated with interferon alpha.The following points should be considered when initiating Ribavirin tablets combination therapy with peginterferon alfa-2a: 1. Use the dosing syringe provided, or use a medicine dose-measuring device (not a kitchen spoon).Drink extra fluids while you are taking ribavirin to keep from getting dehydrated.Ribavirin can cause dry mouth, which could lead to tooth decay or Take the missed dose on the same day you remember it. Patients with a history of significant or unstable cardiac disease should not be treated with Ribavirin [see WARNINGS AND PRECAUTIONS (Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to Ribavirin. Soriano V, Puoti M, Sulkowski M, et al. "Product Information. BMJ 336 (2008): 50518. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking Ribavirin therapy and for 6 months post therapy. Sustained virological response (SVR) was defined as undetectable (less than 50 IU/mL) HCV RNA on or after study week 68. "Ribavirin: indications for use in pediatrics." suspension contains 10 mg or 40 mg of fluconazole. In rare cases, this can lead to fatal heart problems. Do not give Ribavirin to other people, even if they have the same symptoms that you have. Didanosine or its active metabolite (dideoxyadenosine 5'-triphosphate) concentrations are increased when didanosine is co-administered with Ribavirin, which could cause or worsen clinical toxicities. Other symptoms of overdose may include: nausea, vomiting, dizziness, fainting, loss of appetite, trouble sleeping, or impaired taste. Severe adverse events were reported in 2 subjects in the peginterferon alfa-2a plus Ribavirin combination therapy group (hyperglycemia and cholecystectomy). Conjunctivitis (up to 5%) has been reported with ribavirin capsules/oral solution in combination with peginterferon alfa-2b or interferon alfa-2b. Anemia (hemoglobin less than 10 g/dL) was observed in 13% of all Ribavirin and peginterferon alfa-2a combination-treated patients in clinical trials. Patients with genotype 1 and high viral titer (defined as greater than 2 x 10HCV 1 and 4–Irrespective of baseline viral titer, treatment for 48 weeks with peginterferon alfa-2a and 1000 mg or 1200 mg of Ribavirin resulted in higher SVR (defined as undetectable HCV RNA at the end of the 24 week treatment-free follow-up period) compared to shorter treatment (24 weeks) and/or 800 mg Ribavirin.HCV 2 and 3– Irrespective of baseline viral titer, treatment for 24 weeks with peginterferon alfa-2a and 800 mg of Ribavirin resulted in a similar SVR compared to longer treatment (48 weeks) and/or 1000 mg or 1200 mg of Ribavirin (see The numbers of patients with genotype 5 and 6 were too few to allow for meaningful assessment. Shults RA, Baron S, Decker J, Deitchman SD, Conner JD "Health care worker exposure to aerosolized ribavirin: biological and air monitoring." Ribavirin systemic 200 mg (RIBAVIRIN 200mg GG 608) J Viral Hepat 19 Suppl 1 (2012): 14-716. In the pediatric study, the most common adverse events in subjects treated with combination therapy peginterferon alfa-2a and Ribavirin for up to 48 weeks were influenza-like illness (91%), upper respiratory tract infection (60%), headache (64%), gastrointestinal disorder (56%), skin disorder (47%), and injection-site reaction (45%). Assignment to the four treatment arms was stratified by viral genotype and baseline HCV viral titer. If any symptom persists or gets worse, or you notice any other symptom not listed, call your doctor immediately.Always consult a medical doctor or patient care specialist before using ribavirin injection.Ribavirin is indicated in the treatment of chronic hepatitis C, a viral infection of the liver.